3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
10
Neoplasm Metastasis
4
Neoplasms by Site
3
Neoplasms
3
Breast Diseases
3
Advanced Breast Cancer
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Skin Diseases
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
ER+ HER2- Advanced Breast Cancer
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
Letrozole
5
Fulvestrant
5
trastuzumab deruxtecan
3
Injections
3
toripalimab
2
sacituzumab govitecan
2
palbociclib
2
elacestrant
2
abemaciclib
2
Anastrozole
2
AZD9833
2
ribociclib
1
pyrotinib
1
exemestane
1
eribulin
1
disitamab vedotin
1
dalpiciclib
1
Vinorelbine
1
Selective Estrogen Receptor Modulators
1
Ritonavir
1
Radiotherapy
1
RAD1901
1
Paclitaxel
1
Lead
1
Itraconazole
1
Goserelin
1
Gonadotropin-Releasing Hormone
1
Everolimus
1
Docetaxel
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Advanced Breast Cancer
×
AZD9833
×
1 year
×
Clear all
NCT07427394
2026-05-28
SERENA-1b
AstraZeneca
Phase 2
Recruiting
24 enrolled
NCT06380751
2026-05-15
EvoPAR-BR01
AstraZeneca
Phase 3
Recruiting
500 enrolled